Galectin 9 Antikörper (AA 200-355)

Produktnummer ABIN8093296

Dieser Maus Monoklonal Antikörper detektiert spezifisch Galectin 9 in IHC. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Galectin 9 Antikörper (AA 200-355) (ABIN8093296)

Target: Galectin 9 (LGALS9) (Lectin, Galactoside-Binding, Soluble, 9 (LGALS9))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Galectin 9 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Güteklasse: Carrier-free

Klon: LGALS9-7689

Produktdetails anti-Galectin 9 Antikörper

Bindungsspezifität: AA 200-355

Verwendungszweck: LGALS9 Antibody / Galectin 9 (azide and preservative free)

Immunogen: A recombinant fragment (around amino acids 200-355) of human LGALS9 protein (exact sequence is proprietary) was used as the immunogen for the LGALS9/Galectin 9 antibody.

Isotyp: IgG2, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the LGALS9/Galectin 9 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: LGALS9/Galectin 9 antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Details zu Galectin 9

Target: Galectin 9 (LGALS9) (Lectin, Galactoside-Binding, Soluble, 9 (LGALS9))

Andere Bezeichnung: LGALS9

Hintergrund: LGALS9 Antibody recognizes Galectin 9, also known as Lectin galactoside-binding soluble 9, a beta-galactoside-binding lectin encoded by the LGALS9 gene. Galectin 9 antibody is widely referenced in immunology literature as LGALS9 antibody and Gal-9 antibody due to its established role in immune regulation and tumor immunology. Galectin 9 belongs to the galectin family of carbohydrate-binding proteins characterized by conserved carbohydrate recognition domains that bind beta-galactoside-containing glycoconjugates.

Galectin 9 is expressed in a variety of immune and epithelial cell types and can localize to the cytoplasm, nucleus, and extracellular space depending on cellular context. Structurally, Galectin 9 contains two tandem carbohydrate recognition domains connected by a linker peptide, allowing it to crosslink glycoproteins on the cell surface. This structural organization enables Galectin 9 to modulate cell adhesion, apoptosis, and immune checkpoint signaling pathways. LGALS9 antibody is commonly used in studies evaluating Galectin 9 expression in inflammatory diseases, viral infections, and cancer microenvironments.

Functionally, Galectin 9 is best known for its interaction with immune regulatory receptors such as TIM-3, influencing T cell exhaustion, tolerance, and immune homeostasis. Through these interactions, Galectin 9 participates in the regulation of innate and adaptive immune responses. Altered expression of LGALS9 has been reported in multiple tumor types, where Galectin 9 expression may correlate with immune infiltration and tumor immune evasion mechanisms. As a result, Galectin 9 antibody is frequently utilized in tumor immunology and biomarker research settings.

Beyond immune modulation, Galectin 9 has been implicated in cell aggregation, apoptosis induction, and regulation of cytokine production. Differential expression patterns across tissues and disease states make LGALS9 Antibody a valuable tool for examining Galectin 9 distribution and its role in immune checkpoint biology, inflammatory signaling, and cancer-associated immune landscapes.

UniProt: O00182